top of page

Mwandishi:

Mhariri:

Imeboershwa:

ULY CLINIC

ULY CLINIC

17 Februari 2026, 14:31:27

Mycetoma (Madura Foot)
Mycetoma (Madura Foot)

Mycetoma (Madura Foot)

Mycetoma, also known as Madura Foot, is a chronic, progressive infection of the skin, subcutaneous tissue, and sometimes bone.

  • It is caused either by bacteria (Actinomycetoma) or fungi (Eumycetoma).

  • The disease often develops slowly over months to years, leading to disfiguring lesions if untreated.

  • Commonly affected populations include farmers, barefoot laborers, or individuals in rural, tropical, and subtropical regions.

  • The most frequent site of involvement is the foot, but other areas such as legs, arms, buttocks, scalp, and trunk can also be affected.

  • Early recognition is crucial to prevent permanent deformity, disability, and secondary infections.


Etiology:

  • Actinomycetoma: caused by filamentous bacteria such as Nocardia, Streptomyces, or Actinomadura species

  • Eumycetoma: caused by fungi such as Madurella mycetomatis, Fusarium, or Acremonium species


Signs & Symptoms

  • Initial lesion: Small, painless nodule at the site of inoculation

  • Progression: Nodules enlarge slowly over months to years

  • Characteristic discharging sinuses:

    • Sinuses drain grains (microcolonies)

    • Actinomycetoma: white, yellow, or pale grains

    • Eumycetoma: black grains

  • Pain: Often mild initially; may precede rupture of sinuses

  • Swelling and deformity: Chronic disease may lead to fibrosis, lymphedema, or bone involvement

  • Common localization:

    • Foot (most common) – plantar, dorsum, or toes

    • Legs, arms, buttocks, scalp, trunk


Complications:

  • Secondary bacterial infections

  • Osteomyelitis in long-standing disease

  • Functional impairment due to deformity


Diagnostic Criteria

Clinical features consistent with Mycetoma:
  • Slow-growing subcutaneous nodules

  • Multiple sinuses with visible grains

  • Typical locations: foot, legs, arms, buttocks, scalp, trunk

  • Pain preceding sinus discharge

  • Chronic course over months to years


Differentiation of type:
  • Actinomycetoma: pale white/yellow grains; often responds well to antibiotics

  • Eumycetoma: black grains; often requires prolonged antifungal therapy ± surgery


Investigation

  • Microscopic examination of grains (Gram stain, KOH mount)

  • Culture for bacterial or fungal identification

  • Histopathology of biopsy if diagnosis unclear

  • Imaging:

    • X-ray: detect bone involvement

    • Ultrasound/MRI: assess soft tissue and sinus tracts

  • Blood tests if prolonged antimicrobial therapy is planned (especially for co-trimoxazole)


Treatment


Non-Pharmacological Treatment

  • Surgical intervention: Excision or debridement may be indicated for localized lesions

  • Protective measures: Footwear and protective clothing in at-risk populations, e.g., farmers or those in contact with contaminated soil or cattle dung

  • Patient education: Emphasize early treatment to prevent deformity


Pharmacological Treatment


Actinomycetoma (Bacterial form):

Combination therapy options:

  • Co-trimoxazole (PO) 480–960 mg 12 hourly for 5 weeksAND

    • Streptomycin or Amikacin for 5 weeks

Alternative:

  • Co-trimoxazole (PO) 480–960 mg 12 hourly for 5 weeksAND

    • Dapsone (PO):

      • Adults: 100 mg once daily for 2–4 months

      • Children: 25–50 mg once daily for 5 weeks


Monitoring:

  • Regular blood tests (CBC, liver function) if co-trimoxazole or Dapsone therapy exceeds 14 days

Eumycetoma (Fungal form):

  • Itraconazole 200 mg PO twice daily for 5 weeks to 12 months depending on severity and response

  • Surgery is often performed prior to antifungal therapy for debulking lesions

Adjunct therapy:

  • Analgesics for pain control

  • Management of secondary bacterial infections if present


Prevention

  • Avoid barefoot walking in endemic areas

  • Use protective footwear and gloves when handling soil or animals

  • Early recognition and treatment of minor skin injuries

  • Community health education on risks and hygiene


References

  1. van de Sande WWJ. Global burden of human mycetoma: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2013;7(11):e2550.

  2. Ahmed AO, van de Sande WWJ, et al. Mycetoma caused by Madurella mycetomatis: a neglected infectious burden. Lancet Infect Dis. 2004;4:566–574.

  3. Fahal AH. Mycetoma: A thorn in the flesh. Trans R Soc Trop Med Hyg. 2004;98:3–11.

  4. Tanzania Ministry of Health. Standard Treatment Guidelines & National Essential Medicines List (STG/NEMLIT). 7th ed. Dodoma: MoH; 2023.


Imeandikwa;

3 Novemba 2020, 11:19:13

bottom of page